Hostname: page-component-8448b6f56d-mp689 Total loading time: 0 Render date: 2024-04-19T04:43:04.468Z Has data issue: false hasContentIssue false
  • English
  • Français

Long-term effects of pharmacotherapy on relapse prevention in alcohol dependence

Published online by Cambridge University Press:  24 June 2014

F. Kiefer ,
F. Andersohn ,
C. Otte ,
K. Wolf ,
H. Jahn  and
K. Wiedemann
F. Kiefer*
Affiliation:
Department of Addictive Behaviour and Addiction Medicine, Central Institute of Mental Health (CIMH), University of Heidelberg, Mannheim, Germany Department of Psychiatry and Psychotherapy, University Hospital of Hamburg, Hamburg, Germany
F. Andersohn
Affiliation:
Department of Psychiatry and Psychotherapy, University Hospital of Hamburg, Hamburg, Germany
C. Otte
Affiliation:
Department of Psychiatry and Psychotherapy, University Hospital of Hamburg, Hamburg, Germany
K. Wolf
Affiliation:
Department of Psychiatry and Psychotherapy, University Hospital of Hamburg, Hamburg, Germany
H. Jahn
Affiliation:
Department of Psychiatry and Psychotherapy, University Hospital of Hamburg, Hamburg, Germany
K. Wiedemann
Affiliation:
Department of Psychiatry and Psychotherapy, University Hospital of Hamburg, Hamburg, Germany
*
Falk Kiefer, Department of Addictive Behaviour and Addiction Medicine, Central Institute of Mental Health (CIMH), University of Heidelberg, J5, 68159 Mannheim (Germany),Tel: (49) 621 1703 3502; Fax: (49) 621 1703 3505; E-mail: kiefer@zi-mannheim.de
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

There is growing evidence that pharmacological treatment with two of the best validated anticraving drugs, acamprosate and naltrexone, is efficacious in promoting abstinence in recently detoxified alcohol-dependent subjects.

Objective:

The stability of effects after termination of treatment remains to be answered, especially when combining both the drugs.

Method:

After detoxification, 160 alcohol-dependent subjects participated in a randomized, double-blind, placebo-controlled trial. Patients received naltrexone or acamprosate or a combination of naltrexone and acamprosate or placebo for 12 weeks. Patients were assessed weekly by interview, self-report, questionnaires and laboratory screening. Additionally, follow-up evaluation based on telephone interview of participants, general practitioners and relatives was conducted 12 weeks after terminating the medication.

Results:

At week 12, the proportion of subjects relapsing to heavy drinking was significantly lower in the group with combined medication compared with both placebo and acamprosate (P < 0.05). No difference was detectable between acamprosate and naltrexone, both of which were superior to placebo (P < 0.05). Relapse rates were 28% (combined medication), 35% (naltrexone), 50% (acamprosate) and 75% (placebo). After follow-up (week 24), combined medication led to relapse rates significantly lower than placebo, but not lower than acamprosate. Again, both naltrexone and acamprosate were superior to placebo. Relapse rates were 80% (placebo), 54% (acamprosate), 53% (naltrexone) and 34% (combined medication).

Conclusions:

The results of this study highlight the stability of effects of pharmacotherapy on relapse prevention in alcohol dependence.

Keywords

AlcoholismTreatmentAcamprosateNaltrexoneCravingAbstinenceTrial
Type
Original Article
Information
Acta Neuropsychiatrica , Volume 16 , Issue 5 , October 2004 , pp. 233 - 238
Copyright
Copyright © 2004 Blackwell Munksgaard

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Kranzler, HR. Pharmacotherapy of alcoholism: gaps in knowledge and opportunities for research. Alcohol Alcohol 2000;35: 537–547.CrossRefGoogle ScholarPubMed
Rammes, G, Mahal, B, Putzke, Jet al. The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801. Neuropharmacology 2001;40: 749–760.DOI: 10.1016/S0028-3908(01)00008-9CrossRefGoogle ScholarPubMed
Zeise, ML, Kasparov, S, Capogna, M, Zieglgansberger, W. Acamprosate (calciumacetylhomotaurinate) decreases postsynaptic potentials in the rat neocortex: possible involvement of excitatory amino acid receptors. Eur J Pharmacol 1993;231: 47–52.DOI: 10.1016/0014-2999(93)90682-8CrossRefGoogle ScholarPubMed
Boismare, F, Daoust, M, Moore, Net al. A homotaurine derivative reduces the voluntary intake of ethanol by rats: are cerebral GABA receptors involved? Pharmacol Biochem Behav 1984;21: 787–789.CrossRefGoogle ScholarPubMed
Gewiss, M, Heidbreder, C, Opsomer, L, Durbin, P, De Witte, P. Acamprosate and diazepam differentially modulate alcohol-induced behavioural and cortical alterations in rats following chronic inhalation of ethanol vapour. Alcohol Alcohol 1991;26: 129–137.CrossRefGoogle ScholarPubMed
Littleton, J. Acamprosate in alcohol dependence: how does it work? Addiction 1995;90: 1179–1188.DOI: 10.1046/j.1360-0443.1995.90911793.xCrossRefGoogle ScholarPubMed
Lhuintre, JP, Daoust, M, Moore, NDet al. Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcohol dependent subjects. Lancet 1985;1: 1014–1016.DOI: 10.1016/S0140-6736(85)91615-0CrossRefGoogle Scholar
Lhuintre, JP, Moore, N, Tran, Get al. Acamprosate appears to decrease alcohol intake in weaned alcohol dependent subjects. Alcohol Alcohol 1990;25: 613–622.CrossRefGoogle Scholar
Pelc, I, Le Bon, O, Verbanck, P, Lehnert, PH, Opsomer, L. Calcium acetyl homotaurinate for maintaining abstinence in weaned alcoholic patients; a placebo-controlled double-blind multi-centre study. In: Naranjo, C, Sellers, EM, eds. Novel pharmacological interventions for alcoholism. New York: Springer-Verlag, 1992: 348–352. CrossRefGoogle Scholar
Ladewig, D, Knecht, T, Leher, P, Fendl, A. Acamprosate – a stabilizing factor in long-term withdrawal of alcoholic patients. Ther Umsch 1993;50: 182–188.Google ScholarPubMed
Paille, FM, Guelfi, JD, Perkins, AC, Royer, RJ, Steru, L, Parot, P. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol 1995;30: 239–247.Google ScholarPubMed
Roussaux, JP, Hers, D, Ferauge, M. Does acamprosate diminish the appetite for alcohol in weaned alcohol dependent subjects? J Pharm Belg 1996;51: 65–68.Google Scholar
Whitworth, AB, Fischer, F, Lesch, OMet al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 1996;347: 1438–1442.DOI: 10.1016/S0140-6736(96)91682-7CrossRefGoogle ScholarPubMed
Sass, H, Soyka, M, Mann, K, Zieglgansberger, W. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 1996;53: 673–680[erratum appears in Arch Gen Psychiatry 1996;53 (12):1097].CrossRefGoogle ScholarPubMed
Pelc, I, Verbanck, P, Le Bon, O, Gavrilovic, M, Lion, K, Lehert, P. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. Br J Psychiatry 1997;171: 73–77.CrossRefGoogle ScholarPubMed
Geerlings, PJ, Ansoms, C, Van Den Brink, W. Acamprosate and prevention of relapse in alcohol dependent subjects. Eur Addict Res 1997;3: 129–137. CrossRefGoogle Scholar
Poldrugo, F. Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction 1997;92: 1537–1546.DOI: 10.1046/j.1360-0443.1997.9211153713.xCrossRefGoogle Scholar
Besson, J, Aeby, F, Kasas, A, Lehert, P, Potgieter, A. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res 1998;22: 573–579.CrossRefGoogle ScholarPubMed
Tempesta, E, Janiri, L, Bignamini, A, Chabac, S, Potgieter, A. Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol 2000;35: 202–209.CrossRefGoogle ScholarPubMed
Chick, J, Howlett, H, Morgan, MY, Ritson, B. United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol 2000;35: 176–187.CrossRefGoogle ScholarPubMed
Namkoong, K, Lee, BO, Lee, PG, Choi, MJ, Lee, E. Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study. Alcohol Alcohol 2003;38: 135–141.CrossRefGoogle ScholarPubMed
Wilde, MI, Wagstaff, AJ. Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drugs 1997;53: 1038–1053[Review].CrossRefGoogle ScholarPubMed
Volpicelli, JR, Alterman, AI, Hayashida, M, O'Brien, CP. Naltrexone in the treatment of alcohol dependence [see comments]. Arch Gen Psychiatry 1992;49: 876–880.CrossRefGoogle Scholar
O'Malley, SS, Jaffe, AJ, Chang, G, Schottenfeld, RS, Meyer, RE, Rounsaville, B. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry 1992;49: 881–887.CrossRefGoogle ScholarPubMed
Anton, RF, Moak, DH, Waid, LR, Latham, P, Malcolm, R, Dias, JK. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcohol dependent subjects: results of a placebo-controlled trial. Am J Psychiatry 1999;156: 1758–1764.Google ScholarPubMed
Chick, J, Anton, R, Checinski, Ket al. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol 2000;35: 587–593.CrossRefGoogle ScholarPubMed
Lee, A, Tan, S, Lim, Det al. Naltrexone in the treatment of male alcohol dependent subjects – an effectiveness study in Singapore. Drug Alcohol Rev 2001;20: 193–199.DOI: 10.1080/09595230120058579CrossRefGoogle Scholar
Oslin, D, Liberto, JG, O'Brien, J, Krois, S, Norbeck, J. Naltrexone as an adjunctive treatment for older patients with alcohol dependence. Am J Geriatr Psychiatry 1997;5: 324–332.CrossRefGoogle ScholarPubMed
Kranzler, HR, Modesto-Lowe, V, Van Kirk, J. Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial. Neuropsychopharmacology 2000;22: 493–503.DOI: 10.1016/S0893-133X(99)00135-9CrossRefGoogle ScholarPubMed
Morris, PL, Hopwood, M, Whelan, G, Gardiner, J, Drummond, E. Naltrexone for alcohol dependence: a randomized controlled trial. Addiction 2001;96: 1565–1573.DOI: 10.1046/j.1360-0443.2001.961115654.xCrossRefGoogle ScholarPubMed
Monti, PM, Rohsenow, DJ, Swift, RMet al. Naltrexone and cue exposure with coping and communication skills training for alcohol dependent subjects: treatment process and 1-year outcomes. Alcohol Clin Exp Res 2001;25: 1634–1647.DOI: 10.1097/00000374-200111000-00011CrossRefGoogle Scholar
Krystal, JH, Cramer, JA, Krol, WF, Kirk, GF, Rosenheck, RA. Naltrexone in the treatment of alcohol dependence. N Engl J Med 2001;345: 1734–1739.DOI: 10.1056/NEJMoa011127CrossRefGoogle ScholarPubMed
Gastpar, M, Bonnet, U, Boning, Jet al. Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. J Clin Psychopharmacol 2002;22: 592–598.DOI: 10.1097/00004714-200212000-00009CrossRefGoogle ScholarPubMed
Croop, RS, Faulkner, EB, Labriola, DF. The safety profile of naltrexone in the treatment of alcoholism. Arch Gen Psychiatry 1997;54: 1130–1134.CrossRefGoogle ScholarPubMed
Kiefer, F, Jahn, H, Tarnaske, Tet al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2003;60: 92–99.CrossRefGoogle ScholarPubMed
Anton, RF, Moak, DH, Latham, P. The Obsessive Compulsive Drinking Scale. A self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res 1995;19: 92–99.CrossRefGoogle ScholarPubMed
Mann, K, Ackermann, K. Die OCDS-G: Psychometrische Kennwerte der deutschen Version der Obsessive Compulsive Drinking Scale. Sucht 2000;2: 90–100. CrossRefGoogle Scholar
Schoechlin, C, Engel, RR. Meta-analysis of pharmacotherapeutic trials. In: Zernig, G, Saria, A, Kurz, M, O'Malley, SS, eds. Handbook of alcoholism. Boca Raton: CRC Press, 2000: 339–352. CrossRefGoogle Scholar
Kranzler, HR, Van Kirk, J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 2001;25: 1335–1341.DOI: 10.1097/00000374-200109000-00014CrossRefGoogle ScholarPubMed
Rubio, G, Jiménez-Arriero, MA, Ponce, G, Palomo, T. Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment. Alcohol Alcohol 2001;36: 419–425.CrossRefGoogle ScholarPubMed
Stromberg, MF, Mackler, SA, Volpicelli, JR, O'Brien, CP. Effect of acamprosate and naltrexone, alone or in combination, on ethanol consumption. Alcohol 2001;23: 109–116.DOI: 10.1016/S0741-8329(00)00137-3CrossRefGoogle ScholarPubMed
Heyser, CJ, Moc, K, Koob, GF. Effects of naltrexone alone and in combination with acamprosate on the alcohol deprivation effect in rats. Neuropsychopharmacology 2003;28: 1463–1471.DOI: 10.1038/sj.npp.1300175CrossRefGoogle ScholarPubMed
Mason, BJ, Goodman, AM, Dixon, RMet al. A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology 2002;27: 596–606.DOI: 10.1016/S0893-133X(02)00368-8CrossRefGoogle ScholarPubMed
O'Malley, SS, Carroll, KM. Psychotherapeutic considerations in pharmacological trials. Alcohol Clin Exp Res 1996;20: 17A–22A.CrossRefGoogle ScholarPubMed